Porton Fine Chemicals vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Porton Fine Chemicals Ltd (300363.CS)

Q3 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

August 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Latest14 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.